REGULATORY

OxyContin Gets Delayed Approval in Japan with Special Distribution Scheme Now in Place

October 30, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) on October 29 approved Shionogi’s opioid analgesic OxyContin (oxycodone) for an additional indication of chronic pain with a seven-month delay from the typical timeline as it sees a special distribution scheme now…

To read the full story

OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020

REGULATORY

Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
PM Vows Comprehensive Support for 17 Priority Sectors: Policy Speech
February 24, 2026
Multiple Drug-Drug Interaction Risks under PMDA Review
February 24, 2026
Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
Health Minister Signals Early March Approval for iPSC Products
February 20, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…